CompletedPhase 2NCT00449748
Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis
Studying Mastocytosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Srdan Verstovsek, MDM.D. Anderson Cancer Center
- Intervention
- RAD001 (Everolimus)(drug)
- Enrollment
- 10 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2007 – 2009
Study locations (1)
- The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Collaborators
Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00449748 on ClinicalTrials.govOther trials for Mastocytosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07328178Analysis of the Role of IgE Proteoforms in Health and DiseaseKU Leuven
- RECRUITINGPHASE4NCT06748001Avapritinib Rollover StudyBlueprint Medicines Corporation
- RECRUITINGNCT06466889Mastocytosis Registry (of Zurich)University of Zurich
- ACTIVE NOT RECRUITINGNCT06065007Quality of Life and Disease-related Symptoms in Individuals With Systemic MastocytosisUppsala University
- RECRUITINGPHASE1NCT06327685Avapritinib With Decitabine in Patients With SM-AHNH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNCT06440148Relationship Between Circulating Sclerostin and Bone Lesions in Patients With MastocytosisMedical University of Lublin
- RECRUITINGNCT00044122Study of Factors Regulating Mast Cell ProliferationNational Institute of Allergy and Infectious Diseases (NIAID)